Xeris Biopharma Holdings, Inc. (XERS)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
XERS posts 2024 revenue of $217 million, maintains $201M cash reserves
# 🧾 What This Document Is This is the 2025 Annual Report (Form 10-K) for Xeris Biopharma. Think of it as the company's official, comprehensive report card for the entire year. It’s filed with the SEC and is packed with detailed information about the business, its financial results, the risks it fac
XERS Sets 2026 Annual Meeting to Vote on Directors and Executive Pay
# 🧾 What This Document Is — Your Invitation to a Company Vote This is a **proxy statement** (Form DEF 14A) for Xeris Biopharma. Think of it as an official invitation and handbook for the company's annual meeting. Its job is to give shareholders the information they need to vote on important compan
SEC filings
All filings →Insider trades
All insider trades →Xeris Biopharma Holdings, Inc. has no reported insider trades in the last 90 days.